CA3072455A1 - Pyruvate kinase modulators and use thereof - Google Patents

Pyruvate kinase modulators and use thereof Download PDF

Info

Publication number
CA3072455A1
CA3072455A1 CA3072455A CA3072455A CA3072455A1 CA 3072455 A1 CA3072455 A1 CA 3072455A1 CA 3072455 A CA3072455 A CA 3072455A CA 3072455 A CA3072455 A CA 3072455A CA 3072455 A1 CA3072455 A1 CA 3072455A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
protecting group
instance
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072455A
Other languages
English (en)
French (fr)
Inventor
Giovanni Cianchetta
Charles KUNG
Tao Liu
Anil Kumar PADYANA
Zhihua Sui
Zhenwei CAI
Dawei Cui
Jingjing Ji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CA3072455A1 publication Critical patent/CA3072455A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3072455A 2017-08-15 2018-08-15 Pyruvate kinase modulators and use thereof Pending CA3072455A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
CNPCT/CN2017/097496 2017-08-15
US201862673526P 2018-05-18 2018-05-18
US201862673533P 2018-05-18 2018-05-18
US62/673,533 2018-05-18
US62/673,526 2018-05-18
PCT/US2018/000129 WO2019035865A1 (en) 2017-08-15 2018-08-15 MODULATORS OF PYRUVATE KINASE AND THEIR USE

Publications (1)

Publication Number Publication Date
CA3072455A1 true CA3072455A1 (en) 2019-02-21

Family

ID=63524352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072455A Pending CA3072455A1 (en) 2017-08-15 2018-08-15 Pyruvate kinase modulators and use thereof

Country Status (34)

Country Link
US (8) US11464775B2 (cg-RX-API-DMAC10.html)
EP (4) EP3668513B1 (cg-RX-API-DMAC10.html)
JP (5) JP7301040B2 (cg-RX-API-DMAC10.html)
KR (3) KR102642408B1 (cg-RX-API-DMAC10.html)
CN (3) CN117186119B (cg-RX-API-DMAC10.html)
AU (4) AU2018316587B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020003254A2 (cg-RX-API-DMAC10.html)
CA (1) CA3072455A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020000375A1 (cg-RX-API-DMAC10.html)
CO (2) CO2020002959A2 (cg-RX-API-DMAC10.html)
CR (1) CR20200123A (cg-RX-API-DMAC10.html)
CY (1) CY1124953T1 (cg-RX-API-DMAC10.html)
DK (2) DK3668513T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP20018487A (cg-RX-API-DMAC10.html)
ES (3) ES2966825T3 (cg-RX-API-DMAC10.html)
FI (1) FI3668512T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20230452T1 (cg-RX-API-DMAC10.html)
HU (2) HUE061910T2 (cg-RX-API-DMAC10.html)
IL (3) IL272599B (cg-RX-API-DMAC10.html)
LT (2) LT3668512T (cg-RX-API-DMAC10.html)
MD (1) MD3668513T2 (cg-RX-API-DMAC10.html)
MX (2) MX2020001833A (cg-RX-API-DMAC10.html)
MY (1) MY204421A (cg-RX-API-DMAC10.html)
PE (1) PE20200724A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020500343B1 (cg-RX-API-DMAC10.html)
PL (2) PL3668512T3 (cg-RX-API-DMAC10.html)
PT (2) PT3668512T (cg-RX-API-DMAC10.html)
RS (2) RS62871B1 (cg-RX-API-DMAC10.html)
SG (2) SG11202001353PA (cg-RX-API-DMAC10.html)
SI (2) SI3668513T1 (cg-RX-API-DMAC10.html)
SM (2) SMT202200023T1 (cg-RX-API-DMAC10.html)
TW (3) TWI790271B (cg-RX-API-DMAC10.html)
UA (1) UA126292C2 (cg-RX-API-DMAC10.html)
WO (3) WO2019035863A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
EP3668513B1 (en) 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US12233063B2 (en) 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
KR102794329B1 (ko) * 2019-06-26 2025-04-14 닛산 가가쿠 가부시키가이샤 전하 수송성 바니시
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
CA3183980A1 (en) * 2020-07-21 2022-01-27 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
KR20240107326A (ko) * 2021-11-16 2024-07-09 아지오스 파마슈티컬스 아이엔씨. Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
EP4671102A1 (en) 2023-03-28 2025-12-31 Honda Motor Co., Ltd. METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS
WO2024238659A1 (en) 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
CN121443584A (zh) * 2023-07-05 2026-01-30 安吉奥斯医药品有限公司 丙酮酸激酶活化剂的合成
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
WO2026096368A1 (en) 2024-10-28 2026-05-07 Agios Pharmaceuticals, Inc. Use of the pyruvate kinase activator tebapivat in the treatment of renal fibrosis and other renal diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
BR0012896A (pt) 1999-07-30 2002-06-18 Abbott Gmbh & Co Kg 2-pirazolin-5-onas
CZ2002773A3 (cs) 1999-09-04 2002-06-12 Astrazeneca Ab Substituované deriváty N-fenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamidu, které zvyąují aktivitu pyruvátdehydrogenázy
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2731432A1 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010025202A1 (en) * 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
ES2620634T3 (es) * 2008-10-09 2017-06-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activadores de piruvato quinasa humana
JP5756457B2 (ja) * 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
US8637536B2 (en) 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
EP2704719B1 (en) * 2011-05-03 2018-02-21 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
EP2704720B1 (en) * 2011-05-03 2019-08-07 Agios Pharmaceuticals, Inc. Pyruvate kinase r activators for use in therapy
EP2734520B1 (en) * 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
NZ707778A (en) 2012-11-08 2019-03-29 Agios Pharmaceuticals Inc Therapeutic compounds and compositions and their use as pkm2 modulators
JP2016506943A (ja) * 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
EP3668513B1 (en) * 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Also Published As

Publication number Publication date
LT3668512T (lt) 2023-06-12
PH12020500343A1 (en) 2021-02-08
US11957680B2 (en) 2024-04-16
JP7301040B2 (ja) 2023-06-30
PL3668512T3 (pl) 2023-06-19
WO2019035863A8 (en) 2019-03-28
PT3668512T (pt) 2023-05-22
HRP20220039T1 (hr) 2022-04-15
CO2020002961A2 (es) 2020-04-13
EP4026838A1 (en) 2022-07-13
IL272599B (en) 2022-08-01
EP3668513A1 (en) 2020-06-24
MD3668513T2 (ro) 2022-04-30
CY1124953T1 (el) 2023-01-05
WO2019035865A8 (en) 2019-03-28
US20230226055A1 (en) 2023-07-20
HUE061910T2 (hu) 2023-08-28
MX2020001832A (es) 2020-07-22
CN111032045B (zh) 2023-08-15
AU2018316587B2 (en) 2023-05-11
US20200207785A1 (en) 2020-07-02
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
KR102764124B1 (ko) 2025-02-05
IL272597A (en) 2020-03-31
JP2023027276A (ja) 2023-03-01
EP3668881B1 (en) 2023-10-04
JP7275107B2 (ja) 2023-05-17
AU2024205818A1 (en) 2024-09-05
WO2019035864A1 (en) 2019-02-21
CN117186119B (zh) 2026-04-28
CN117186119A (zh) 2023-12-08
CN111032046B (zh) 2023-09-26
SG11202001262QA (en) 2020-03-30
ES2966825T3 (es) 2024-04-24
AU2018316587A1 (en) 2020-02-20
JP2023052478A (ja) 2023-04-11
AU2018316588B2 (en) 2023-02-02
SI3668513T1 (sl) 2022-04-29
KR20200054200A (ko) 2020-05-19
IL292530A (en) 2022-06-01
CL2020000375A1 (es) 2020-12-11
SI3668512T1 (sl) 2023-06-30
AU2018316588A1 (en) 2020-02-20
WO2019035864A8 (en) 2019-03-28
PH12020500343B1 (en) 2024-02-21
US20220395503A1 (en) 2022-12-15
KR20230127364A (ko) 2023-08-31
RS62871B1 (sr) 2022-02-28
SMT202300146T1 (it) 2023-07-20
DK3668512T3 (da) 2023-05-22
US11364240B2 (en) 2022-06-21
WO2019035863A1 (en) 2019-02-21
KR102717594B1 (ko) 2024-10-14
RU2020110573A3 (cg-RX-API-DMAC10.html) 2021-12-24
US20220233541A1 (en) 2022-07-28
US11040036B2 (en) 2021-06-22
CA3071993A1 (en) 2019-02-21
HRP20230452T1 (hr) 2023-07-21
JP2024147805A (ja) 2024-10-16
RU2020110573A (ru) 2021-09-16
CR20200123A (es) 2020-06-29
US12133853B2 (en) 2024-11-05
MY204421A (en) 2024-08-28
IL272599A (en) 2020-03-31
SMT202200023T1 (it) 2022-03-21
CN111032045A (zh) 2020-04-17
UA126292C2 (uk) 2022-09-14
TWI790271B (zh) 2023-01-21
RS64221B1 (sr) 2023-06-30
US20210130371A1 (en) 2021-05-06
US20210077490A1 (en) 2021-03-18
BR112020003262A2 (pt) 2020-09-01
TW202323258A (zh) 2023-06-16
US20200206225A1 (en) 2020-07-02
LT3668513T (lt) 2022-03-25
US20250144093A1 (en) 2025-05-08
FI3668512T3 (fi) 2023-05-12
US11590132B2 (en) 2023-02-28
DK3668513T3 (da) 2022-01-10
MX2020001833A (es) 2020-07-22
TW201919631A (zh) 2019-06-01
AU2023202772A1 (en) 2023-05-18
EP3668881A1 (en) 2020-06-24
EP3668512B1 (en) 2023-02-15
KR20200054199A (ko) 2020-05-19
US11464775B2 (en) 2022-10-11
US11872225B2 (en) 2024-01-16
ES2944545T3 (es) 2023-06-22
SG11202001353PA (en) 2020-03-30
HUE057178T2 (hu) 2022-04-28
IL272597B (en) 2022-06-01
CN111032046A (zh) 2020-04-17
ES2905100T3 (es) 2022-04-07
PL3668513T3 (pl) 2022-03-21
TW201920203A (zh) 2019-06-01
KR102642408B1 (ko) 2024-02-28
WO2019035865A1 (en) 2019-02-21
AU2023202772B2 (en) 2024-05-16
ECSP20018487A (es) 2020-05-29
JP2020531432A (ja) 2020-11-05
BR112020003254A2 (pt) 2020-10-27
CO2020002959A2 (es) 2020-04-13
JP2020531443A (ja) 2020-11-05
EP3668513B1 (en) 2021-11-10
JP7530453B2 (ja) 2024-08-07
EP3668512A1 (en) 2020-06-24
PE20200724A1 (es) 2020-07-21
IL292530B2 (en) 2023-06-01
TWI796353B (zh) 2023-03-21

Similar Documents

Publication Publication Date Title
US11872225B2 (en) Pyruvate kinase modulators and use thereof
CN108602776B (zh) 用作irak抑制剂的杂芳基化合物及其用途
CN112236429B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
CA2971640C (en) Cot modulators and methods of use thereof
CA3129829A1 (en) Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
CN107108561A (zh) 用作irak抑制剂的杂芳基化合物及其用途
CN112930213A (zh) 用作布鲁顿酪氨酸激酶(btk)的可逆抑制剂的稠合咪唑并吡啶
RU2797518C2 (ru) Модуляторы пируваткиназы и их применение
HK40030322A (en) Pyruvate kinase modulators and use thereof
HK40030322B (en) Pyruvate kinase modulators and use thereof
HK40043591A (en) Heteroaryl compounds as type ii irak inhibitors and uses thereof
HK1242303A1 (en) Heteroaryl compounds as irak inhibitors and uses thereof
HK1242303B (en) Heteroaryl compounds as irak inhibitors and uses thereof
HK1247918A1 (en) Macrocyclic compounds as irak1/4 inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220913

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240809

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240809

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240809

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240903

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250207

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250213

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250213

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250403

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250403

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250403

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20250721

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250806

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250806

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808